Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 93, Issue 1, 2008, Pages

  Rademaker, K J ^a   De Vries, L S ^a   Uiterwaal, C S P M ^a   Groenendaal, F ^a   Grobbee, D E ^a   Van Bel, F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE;

FOLLOW UP; HUMAN; LUNG DISEASE; NERVE CELL DIFFERENTIATION; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS; CHILD DEVELOPMENT; CHRONIC DISEASE; DEXAMETHASONE; HUMANS; HYDROCORTISONE; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LUNG DISEASES; NERVOUS SYSTEM DISEASES;

EID: 38049115216     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2007.119545     Document Type: Review

References (53)

1. Committee on Obstetric Practice. ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2002;99:871-3.
2. Barrington KJ. Hazards of systemic steroids for ventilator-dependent preterm infants: what would a parent want? CMAJ 2001;165:33-4.
3. Thebaud B, Lacaze-Masmonteil T, Watterberg K. Postnatal glucocorticoids in very preterm infants: "the good, the bad, and the ugly"? Pediatrics 2001;107:413-5.
4. Finer NN, Craft A, Vaucher YE, et al. Postnatal steroids: short-term gain, long-term pain? J Pediatr 2000;137:9-13.
5. Jobe AH. Postnatal corticosteroids for preterm infants - do what we say, not what we do. N Engl J Med 2004;350:1349-51
6. Shinwell ES. Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants. Biol Neonate 2003;84:96-100.
7. Mammel MC, Green TP, Johnson DE, et al. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;1:1356-8
8. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990s. Early Hum Dev 1999;53:193-218
9. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;101:E7.
10. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177-181.
11. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21.
12. Shinwell ES, Karplus M, Bader D, et al. Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed 2003;88:F432-3.
13. American Academy of Pediatrics, Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-8.
14. Finer NN, Powers RJ, Ou CH, et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics 2006;117:704-13.
15. Short EJ, Klein NK, Lewis BA, et al. Cognitive and academic conseguences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 2003;112:e359.
16. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304-13.
17. Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics 2007;119:265-72.
18. Ng PC, Lee CH, Bnur FL, et al. A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 2006;117:367-75.
19. Seri I. Hydrocortisone and vasopressor-resistant shock in preterm neonates. Pediatrics 2006;117:516-8.
20. Aucott SW. Hypotension in the newborn: who needs hydrocortisone? J Perinatol 2005;25:77-8.
21. Lattimore KA, Vazguez DM, Barks JD, et al. 12 month developmental outcome in infants treated with hydrocortisone for refractory hypotension. Presented at the Society for Pediatric Research meeting, Toronto, Canada, 2007. E-PAS: 617934.9.
22. Baden M, Bauer CB, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972;50:526-34.
23. Watterberg KL, Gerdes JS, Gifford KL, et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104:1258-63.
24. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995;95:120-5.
25. Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97:210-5.
26. Heide-Jalving M, Kamphuis PJ, van der Laan MJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003;92:827-35.
27. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57.
28. Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005;146:632-7.
29. Bonsante F, Latorre G, Iacobelli S, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology 2007;91:217-21.
30. Taeusch HW Jr, Wang NS, Baden N, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome: II. Pathology. Pediatrics 1973;52:850-4.
31. Fitzhardinge PM, Eisen A, Lejtenyi C, et al. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974;53:877-83.
32. Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007;120:40-8.
33. Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005;116:1-7.
34. Rademaker KJ, Rijpert M, Uiterwaal CS, et al. Neonatal hydrocortisone treatment related to 1H-MBS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res 2006;59:309-13.
35. Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007;150:351-7.
36. Karemaker R, Heijnen CJ, Veen S, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res 2006;60:745-50.
37. De Kloet ER, Vreugdenhil E, Oitzl MS, et al. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998;19:269-301.
38. Sapolsky RM, Uno H, Rebert CS, et al. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990;10:2897-902.
39. Uno H, Tarara R, Else JG, et al. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci 1989;9:1705-11.
40. Almeida OF, Conde GL, Crochemore C, et al. Subtle shifts in the ratio between pro-and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 2000;14:779-90.
41. Holmes MC, Seckl JR. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol 2006;248:9-14
42. Holmes MC, Sangra M, French KL, et al. 11beta- Hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience 2006;137:865- 73.
43. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook, 11th edn. Hudson, OH: Lexi-Comp, 2004.
44. Reist M, Marshall KA, Jenner P, et al. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem 1998;71:2431-8.
45. Baud O, Laudenbach V, Evrard P, et al. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives Pediatr Res 2001;50:706-11.
46. Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006;117:75-83.
47. Doyle LW, Davis PG, Morley CJ, et al. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 2007;119:716-21.
48. Gross SJ, Anbar RD, Mettelman B. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005;115:681-7.
49. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 2001;111:541-5.
50. Caeymaex L, Gatel P, Castel C, et al. Low-dose hydrocortisone alone does not lead to gastro-intestinal perforation in ELBW infants. Presented at the Society for Pediatric Research meeting, San Francisco, CA, USA, E-PAS 2006;50:2861.220.
51. Hallman M, Peltoniemi O. Saarela T. Early neonatal hydrocortisone: study rather than treat. Pediatrics 2006;118:2540-2.
52. Ramanathan R, Siassi B, Sardesai S, et al. Dexamethasone versus hydrocortisone for hypotension refractory to high dose inotropic agents and incidence of candida infection in extremely low birth weight infants. Pediatr Res 2006;39:A240.
53. Botas CM, Kurlat I, Young SM, et al. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 1995;95:883-7.